Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
MHLW Drops 5-Scale CEA Rating, Pitches Slope-Like Price Adjustment Model: Chuikyo
The Ministry of Health, Labor and Welfare (MHLW) on October 4 presented a specific plan for the appraisal process of an ongoing pilot cost-effective assessment (CEA) program, which will involve price adjustments for 13 pharmaceutical and medical device products in…
To read the full story
Related Article
- “Pediatric Treatment”, “Innovation” Excluded from Ethical/Social Factors in Pilot CEA Program: Chuikyo
October 5, 2017
- Chuikyo Mulls over Scope of CEA-Based Price Adjustments - Premium Portion or Total NHI Price?
October 5, 2017
- Payers Oppose Price Hikes based on CEA at 1st Joint Meeting: Chuikyo
October 5, 2017
REGULATORY
- 10 Firms Win Approval for Bilanoa Generics, 2 Contenders for Fycompa
February 17, 2026
- MHLW to Brand OTC-Like Drug Cost Rule as “Partially Non-Insured Care”
February 17, 2026
- Taiyo Pharma’s Propranolol Designated as Drug for Specific Use
February 17, 2026
- Japan Grants Orphan Tag to Bayer, Incyte Drugs, and 12 Others
February 17, 2026
- Japan to Delist 387 Drugs from NHI Price List, Including Renivace
February 16, 2026
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…